• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results.

    Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi.

    To access the Call me™ feature, which avoids having to wait for an operator, click here.

    After the live webcast, the event will be archived on Hyperion Defi's website for one year.

    Annual Meeting

    The management team of Hyperion DeFi reminds investors to vote ahead of the Company's upcoming Annual General Meeting, which is scheduled for Monday, August 18th.

    About Hyperion DeFi, Inc.

    Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE. The Company is focused on providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.

    Hyperion DeFi is also completing development of its Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in better outcomes for patients and providers. The company is currently exploring strategic options for this technology.

    For more information, please visit Hyperiondefi.com.

    Forward Looking Statements

    Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our cryptocurrency treasury strategy, the clinical trials that may be necessary in connection with the clearance of the Optejet UFD, and the timing for sales growth of our approved products. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

    In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; our ability to raise additional funds to maintain our business operations and to make payments on our debt obligations as and when necessary; and the risks of our cryptocurrency strategy as detailed in our Current Report on Form 8-K filed on June 27, 2025.

    Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Hyperion DeFi does not undertake any obligation to update any forward-looking statements.

    Hyperion DeFi, Inc. Investor Contact:

    Eric Ribner

    LifeSci Advisors, LLC

    [email protected]

    (646) 751-4363



    Primary Logo

    Get the next $HYPD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Adds $10M in HYPE to its Treasury Holdings

    LAGUNA HILLS, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), today announced that it has acquired an additional 176,422 HYPE tokens, expanding its total holdings to 1,712,195 HYPE purchased at an average price of $38.25 per token. "The Hyperliquid ecosystem continues to demonstrate the central role that HYPE has in both on-chain governance and enabling the associated governance outcomes, as seen with the recent USDH stablecoin proposals," said Hyunsu Jung, Interim Chief Executive Officer. "Following the upcoming mainnet upgrade, a minimum stake of 200,000 HYPE will be required to qualify as an eligible quote asset on Hyper

    9/25/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

    LAGUNA HILLS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced its first HYPE Asset Use Service ("HAUS") agreement with proprietary trading firm Credo Cayman ("Credo"). Through this first-of-its-kind on-chain service, Hyperion DeFi provides the use of 100,000 staked HYPE to Credo, enabling the firm to substantially reduce transaction fees when trading on Hyperliquid. The resulting net fee savings will be shared between the two companies, creating a new revenue stream for both. "Hyperion DeFi's l

    9/16/25 8:00:39 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Treasury Revolution Accelerates as $113 Billion Bitcoin Holdings Spark 150% Stock Surges

    USA News Group News Commentary Issued on behalf of CEA Industries, Inc. VANCOUVER, BC, Sept. 12, 2025 /PRNewswire/ -- USA News Group News Commentary – Earlier this summer, Animoca Brands released a report stating corporate treasury companies surge an average of 150% within 24 hours of announcing crypto adoption strategies[1] as digital asset treasuries amass $113 billion in Bitcoin stockpiles through September 2025, according to Coingecko data[2]. The explosive momentum reflects a fundamental shift from traditional cash reserves to strategic cryptocurrency accumulation, with U.S. Bank resuming Bitcoin custody services for institutional clients following greater regulatory clarity and institu

    9/12/25 9:00:00 AM ET
    $BNC
    $DFDV
    $HYPD
    Industrial Machinery/Components
    Industrials
    Finance: Consumer Services
    Finance

    $HYPD
    SEC Filings

    View All

    SEC Form 424B5 filed by Hyperion DeFi Inc.

    424B5 - HYPERION DEFI, INC. (0001682639) (Filer)

    9/24/25 7:21:26 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    9/24/25 7:14:07 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    9/8/25 4:12:49 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Walters Happy David was granted 50,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    9/9/25 4:08:07 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Walters Happy David

    3 - HYPERION DEFI, INC. (0001682639) (Issuer)

    9/9/25 4:07:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Jung Hyunsu was granted 1,000,000 shares, increasing direct ownership by 200% to 1,500,000 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    8/20/25 4:49:06 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care